XBiotech Inc
$2.19
$0.01 (+0.46%)
$2.16Day Range$2.22
Key Statistics
Market Cap
$66.46M
Shares Outstanding
30.5M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Apr 15, 2015
Round Lot
100
Locale
US
Trading Data
Day Open
$2.20
Day High
$2.22
Day Low
$2.16
Volume
66.1K
VWAP
$2.19
Prev Close
$2.18
Transactions
--
Acc. Volume
--
About XBiotech Inc
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
PHARMACEUTICAL PREPARATIONSSIC 283487 employees5217 WINNEBAGO LANE, AUSTIN, TX, 78744512-386-2900IPO Apr 15, 2015US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001626878
- Composite FIGI
- BBG0081S8D39
- Share Class FIGI
- BBG0081S8D48
- Ticker Root
- XBIT
- SIC Code
- 2834
About XBiotech Inc (XBIT) Stock
XBiotech Inc (XBIT) closed the 2026-09-18 session at $2.19, up 0.46% versus the previous close (+0.01). The stock opened at $2.20 and traded between $2.16 and $2.22 during that session. Session trading volume was 66K shares. The volume-weighted average price (VWAP) is $2.19.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
XBiotech Inc has a market capitalization of $66.5 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. XBIT is listed on the XNAS exchange. The company employs approximately 87 people. XBiotech Inc is headquartered in AUSTIN, TX. The recorded listing date is 2015-04-15.
On this page you can find market XBIT stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.